Cargando…

Nivolumab infusion reaction manifesting as plantar erythema and pulmonary infiltrate in a lung cancer patient

Infusion reaction is an adverse event of therapeutic monoclonal antibodies. Nivolumab, an anti‐programmed death‐1 antibody, directly activates T cells, which could probably interact with endothelial cells. The etiology of infusion reaction induced by nivolumab may differ from that of other antibodie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ogawara, Daiki, Soda, Hiroshi, Ikehara, Susumu, Sumiyoshi, Makoto, Iwasaki, Keisuke, Okuno, Daisuke, Dohtsu, Yosuke, Taniguchi, Hirokazu, Harada, Tatsuhiko, Fukuda, Yuichi, Mukae, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2017
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668487/ https://www.ncbi.nlm.nih.gov/pubmed/28845909 http://dx.doi.org/10.1111/1759-7714.12494

Ejemplares similares

Remarkable response of nivolumab‐refractory lung cancer to salvage chemotherapy
por: Ogawara, Daiki, et al.
Publicado: (2017)

Dynamics of blood neutrophil‐related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non‐small cell lung cancer: A hypothesis‐generating study
por: Soda, Hiroshi, et al.
Publicado: (2018)

Pulmonary Artery Sarcoma Overexpressing Platelet-derived Growth Factor Receptor α
por: Takemoto, Shinnosuke, et al.
Publicado: (2017)

Presence of few PD‐1‐expressing tumor‐infiltrating immune cells is a potential predictor of improved response to salvage chemotherapy following nivolumab for non‐small cell lung cancer: An exploratory case series
por: Ogawara, Daiki, et al.
Publicado: (2018)

Pulmonary pleomorphic carcinoma with few PD‐1‐positive immune cells and regulatory T cells that showed a complete response to nivolumab
por: Okamura, Kazuaki, et al.
Publicado: (2017)

Successful treatment with nivolumab for lung cancer with low expression of PD‐L1 and prominent tumor‐infiltrating B cells and immunoglobulin G
por: Suyama, Takayuki, et al.
Publicado: (2018)

Alert Regarding Cisplatin-induced Severe Adverse Events in Cancer Patients with Xeroderma Pigmentosum
por: Sumiyoshi, Makoto, et al.
Publicado: (2017)

Pitfalls in diagnosis with the use of circulating tumor‐derived epidermal growth factor receptor mutations in lung cancer harboring pretreatment T790M
por: Ogawara, Daiki, et al.
Publicado: (2017)

Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma
por: Ikeda, Takaya, et al.
Publicado: (2018)

Phase II study of nedaplatin and amrubicin as first‐line treatment for advanced squamous cell lung cancer
por: Taniguchi, Hirokazu, et al.
Publicado: (2019)

Hypertrophic osteoarthropathy associated with lung cancer: Possible links among hypoxia‐inducible factor‐1α, vascular endothelial growth factor, and hypervascularization
por: Tagawa, Ryuta, et al.
Publicado: (2023)

Immunosuppressive tumor microenvironment in extraskeletal myxoid chondrosarcoma: A case of pleural metastases
por: Ogata, Ryosuke, et al.
Publicado: (2022)

Vildagliptin‐induced ground‐glass nodules mimicking lung metastases in a cancer patient receiving Lactobacillus probiotic supplementation
por: Tanaka, Yasuhiro, et al.
Publicado: (2020)

Efficacy of S‐1 after pemetrexed in patients with non‐small cell lung cancer: A retrospective multi‐institutional analysis
por: Takemoto, Shinnosuke, et al.
Publicado: (2021)

Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study
por: Ikeda, Takaya, et al.
Publicado: (2020)

Exploring the ethical complexities of do‐not‐attempt‐resuscitation orders using the approach of advance care planning
por: Ogata, Ryo, et al.
Publicado: (2023)

Palmar and plantar erythema: An initial presentation of undifferentiated connective tissue disease
por: Sow, Yacine, et al.
Publicado: (2023)

Phase I study of pemetrexed and concurrent radiotherapy for previously untreated elderly patients with locally advanced non‐squamous non‐small cell lung cancer
por: Takemoto, Shinnosuke, et al.
Publicado: (2017)

Phase II study of ramucirumab and docetaxel for previously treated non‐small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study
por: Takemoto, Shinnosuke, et al.
Publicado: (2019)

Prediction of Anti-Cancer Drug-Induced Pneumonia in Lung Cancer Patients: Novel High-Resolution Computed Tomography Fibrosis Scoring
por: Gyotoku, Hiroshi, et al.
Publicado: (2020)

Intrathoracic amyloid tumors that presented as yellowish multinodular endobronchial protrusions with irregular vascularity and easy bleeding
por: Tomono, Hiromi, et al.
Publicado: (2019)

Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor
por: Dotsu, Yosuke, et al.
Publicado: (2021)

Necrolytic migratory erythema associated with painful plantar keratoderma. A new diagnostic clue for this paraneoplastic syndrome?()()
por: Gracia-Darder, Inés, et al.
Publicado: (2020)

Phase II trial of a non‐platinum triplet for patients with advanced non‐small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA
por: Takemoto, Shinnosuke, et al.
Publicado: (2019)

HSP47: A Therapeutic Target in Pulmonary Fibrosis
por: Sakamoto, Noriho, et al.
Publicado: (2023)

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
por: Yamaguchi, Ou, et al.
Publicado: (2023)

Nivolumab in non–small cell lung cancer: A novel case of an erythema annulare centrifugum–like eruption
por: Sidiropoulou, Polytimi, et al.
Publicado: (2019)

Phase II study of IRInotecan treatment after COmbined chemo‐immunotherapy for extensive‐stage small cell lung cancer: Protocol of IRICO study
por: Tomono, Hiromi, et al.
Publicado: (2023)

Pulmonary Scedosporium apiospermum Infection with Pulmonary Tumorlet in an Immunocompetent Patient
por: Motokawa, Nana, et al.
Publicado: (2018)

Three distinct mechanisms underlying human γδ T cell-mediated cytotoxicity against malignant pleural mesothelioma
por: Umeyama, Yasuhiro, et al.
Publicado: (2023)

Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib‐resistance of EML4‐ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors
por: Taniguchi, Hirokazu, et al.
Publicado: (2016)

Impact of MET inhibition on small‐cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway
por: Taniguchi, Hirokazu, et al.
Publicado: (2017)

Efficacy and safety of amrubicin hydrochloride for treatment of relapsed small cell lung cancer
por: Ogawara, Daiki, et al.
Publicado: (2010)

Genetic profile of thymic epithelial tumors in the Japanese population: an exploratory study examining potential therapeutic targets
por: Shimada, Midori, et al.
Publicado: (2023)

Onset of pulmonary Epstein–Barr virus‐positive diffuse large B‐cell lymphoma in a patient with silicosis
por: Ogata, Ryosuke, et al.
Publicado: (2021)

Dabrafenib and trametinib therapy in an elderly patient with non‐small cell lung cancer harboring the BRAF V600E mutation
por: Dotsu, Yosuke, et al.
Publicado: (2020)

Pan‐HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK ‐rearranged lung cancer
por: Taniguchi, Hirokazu, et al.
Publicado: (2022)

Erythema Dyschromicum Perstans: Identical to Ashy Dermatosis or Not?
por: Numata, Takafumi, et al.
Publicado: (2015)

Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited‐disease small cell lung cancer: protocol of ACIST study
por: Akagi, Kazumasa, et al.
Publicado: (2022)

Risk factors for an acute exacerbation of idiopathic pulmonary fibrosis
por: Kakugawa, Tomoyuki, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2gm8sn6vs9fku6rfrj95bko1kr